Persons with dispensed medicines; origin
Sex | Age | Origin | Medicine group (ATC) | Periods | Persons with medicines, relative (%) | Defined daily doses (DDD), relative (number per 1 000 persons) |
---|---|---|---|---|---|---|
Total male and female | Total age | Origin: born in the Netherlands | A02 Drugs for acid related disorders | 2022* | 12.78 | 46,484 |
Total male and female | Total age | Origin: born in the Netherlands | A02B Drugs for peptic ulcer and gord | 2022* | 12.78 | 46,483 |
Total male and female | Total age | Origin: born in the Netherlands | A02X Oth. drugs for acid related disord. | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in the Netherlands | A03 Drugs for funct.gastrointest.disord. | 2022* | 2.08 | 1,289 |
Total male and female | Total age | Origin: born in the Netherlands | A03A Drugs for functional bowel disord. | 2022* | 0.50 | 982 |
Total male and female | Total age | Origin: born in the Netherlands | A14 Anabolic agents for systemic use | 2022* | 0.00 | 3 |
Total male and female | Total age | Origin: born in the Netherlands | B Blood and blood forming organs | 2022* | 13.79 | 53,877 |
Total male and female | Total age | Origin: born in the Netherlands | D01 Antifungals for dermatological use | 2022* | 4.52 | 2,734 |
Total male and female | Total age | Origin: born in the Netherlands | D01A Antifungals for topical use | 2022* | 4.14 | 2,422 |
Total male and female | Total age | Origin: born in the Netherlands | D01B Antifungals for systemic use | 2022* | 0.47 | 312 |
Total male and female | Total age | Origin: born in the Netherlands | D03 Means for wounds & ulcers treatment | 2022* | 0.01 | 3 |
Total male and female | Total age | Origin: born in the Netherlands | D05A Antipsoriatics for topical use | 2022* | 0.50 | 995 |
Total male and female | Total age | Origin: born in the Netherlands | D05B Antipsoriatics for systemic use | 2022* | 0.02 | 24 |
Total male and female | Total age | Origin: born in the Netherlands | D06 Antibiotics.. for dermatological use | 2022* | 4.43 | 1,443 |
Total male and female | Total age | Origin: born in the Netherlands | D06A Antibiotics for topical use | 2022* | 3.74 | 1,107 |
Total male and female | Total age | Origin: born in the Netherlands | D06B Chemotherapeutics for topical use | 2022* | 0.75 | 336 |
Total male and female | Total age | Origin: born in the Netherlands | G02B Contraceptives for topical use | 2022* | 0.10 | 1,576 |
Total male and female | Total age | Origin: born in the Netherlands | H02 Corticosteroids for systemic use | 2022* | 4.94 | 3,566 |
Total male and female | Total age | Origin: born in the Netherlands | J General antiinfectives for system.use | 2022* | 19.95 | 3,567 |
Total male and female | Total age | Origin: born in the Netherlands | J01 Antibacterials for systemic use | 2022* | 18.49 | 2,906 |
Total male and female | Total age | Origin: born in the Netherlands | J02 Antimycotics for systemic use | 2022* | 0.87 | 123 |
Total male and female | Total age | Origin: born in the Netherlands | J02A Antimycotics for systemic use | 2022* | 0.87 | 123 |
Total male and female | Total age | Origin: born in the Netherlands | J04A Drugs for treatment of tuberculosis | 2022* | 0.03 | 29 |
Total male and female | Total age | Origin: born in the Netherlands | J04B Drugs for treatment of lepra | 2022* | 0.01 | 22 |
Total male and female | Total age | Origin: born in the Netherlands | J05 Antivirals for systemic use | 2022* | 0.61 | 486 |
Total male and female | Total age | Origin: born in the Netherlands | M05 Drugs for treatment of bone diseases | 2022* | 1.33 | 4,258 |
Total male and female | Total age | Origin: born in the Netherlands | M09 Oth.drugs for musculo-skelet.disord. | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in the Netherlands | R03 Drugs for obstruct. airway diseases | 2022* | 8.80 | 20,813 |
Total male and female | Total age | Origin: born in the Netherlands | R03C Adrenergics for systemic use | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in the Netherlands | R06 Antihistamines for systemic use | 2022* | 7.39 | 11,006 |
Total male and female | Total age | Origin: born in the Netherlands | R06A Antihistamines for systemic use | 2022* | 7.39 | 11,006 |
Total male and female | Total age | Origin: born in the Netherlands | V06A Obesity treatment diet formulations | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin: born in the Netherlands | V06C Infant formulas | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: The Netherlands | A02 Drugs for acid related disorders | 2022* | 13.73 | 50,258 |
Total male and female | Total age | Origin country: The Netherlands | A02B Drugs for peptic ulcer and gord | 2022* | 13.73 | 50,257 |
Total male and female | Total age | Origin country: The Netherlands | A02X Oth. drugs for acid related disord. | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: The Netherlands | A03 Drugs for funct.gastrointest.disord. | 2022* | 2.11 | 1,369 |
Total male and female | Total age | Origin country: The Netherlands | A03A Drugs for functional bowel disord. | 2022* | 0.52 | 1,047 |
Total male and female | Total age | Origin country: The Netherlands | A14 Anabolic agents for systemic use | 2022* | 0.00 | 3 |
Total male and female | Total age | Origin country: The Netherlands | B Blood and blood forming organs | 2022* | 14.64 | 58,067 |
Total male and female | Total age | Origin country: The Netherlands | D01 Antifungals for dermatological use | 2022* | 4.45 | 2,669 |
Total male and female | Total age | Origin country: The Netherlands | D01A Antifungals for topical use | 2022* | 4.08 | 2,356 |
Total male and female | Total age | Origin country: The Netherlands | D01B Antifungals for systemic use | 2022* | 0.46 | 313 |
Total male and female | Total age | Origin country: The Netherlands | D03 Means for wounds & ulcers treatment | 2022* | 0.01 | 3 |
Total male and female | Total age | Origin country: The Netherlands | D05A Antipsoriatics for topical use | 2022* | 0.51 | 1,005 |
Total male and female | Total age | Origin country: The Netherlands | D05B Antipsoriatics for systemic use | 2022* | 0.02 | 25 |
Total male and female | Total age | Origin country: The Netherlands | D06 Antibiotics.. for dermatological use | 2022* | 4.40 | 1,444 |
Total male and female | Total age | Origin country: The Netherlands | D06A Antibiotics for topical use | 2022* | 3.70 | 1,096 |
Total male and female | Total age | Origin country: The Netherlands | D06B Chemotherapeutics for topical use | 2022* | 0.77 | 348 |
Total male and female | Total age | Origin country: The Netherlands | G02B Contraceptives for topical use | 2022* | 0.10 | 1,640 |
Total male and female | Total age | Origin country: The Netherlands | H02 Corticosteroids for systemic use | 2022* | 5.23 | 3,793 |
Total male and female | Total age | Origin country: The Netherlands | J General antiinfectives for system.use | 2022* | 20.14 | 3,657 |
Total male and female | Total age | Origin country: The Netherlands | J01 Antibacterials for systemic use | 2022* | 18.66 | 2,992 |
Total male and female | Total age | Origin country: The Netherlands | J02 Antimycotics for systemic use | 2022* | 0.86 | 124 |
Total male and female | Total age | Origin country: The Netherlands | J02A Antimycotics for systemic use | 2022* | 0.86 | 124 |
Total male and female | Total age | Origin country: The Netherlands | J04A Drugs for treatment of tuberculosis | 2022* | 0.03 | 28 |
Total male and female | Total age | Origin country: The Netherlands | J04B Drugs for treatment of lepra | 2022* | 0.01 | 24 |
Total male and female | Total age | Origin country: The Netherlands | J05 Antivirals for systemic use | 2022* | 0.62 | 489 |
Total male and female | Total age | Origin country: The Netherlands | M05 Drugs for treatment of bone diseases | 2022* | 1.44 | 4,636 |
Total male and female | Total age | Origin country: The Netherlands | M09 Oth.drugs for musculo-skelet.disord. | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: The Netherlands | R03 Drugs for obstruct. airway diseases | 2022* | 8.92 | 21,890 |
Total male and female | Total age | Origin country: The Netherlands | R03C Adrenergics for systemic use | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: The Netherlands | R06 Antihistamines for systemic use | 2022* | 7.18 | 11,224 |
Total male and female | Total age | Origin country: The Netherlands | R06A Antihistamines for systemic use | 2022* | 7.18 | 11,224 |
Total male and female | Total age | Origin country: The Netherlands | V06A Obesity treatment diet formulations | 2022* | 0.00 | 0 |
Total male and female | Total age | Origin country: The Netherlands | V06C Infant formulas | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | A02 Drugs for acid related disorders | 2022* | 0.53 | 416 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | A02B Drugs for peptic ulcer and gord | 2022* | 0.53 | 416 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | A02X Oth. drugs for acid related disord. | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | A03 Drugs for funct.gastrointest.disord. | 2022* | 0.32 | 56 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | A03A Drugs for functional bowel disord. | 2022* | 0.03 | 33 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | A14 Anabolic agents for systemic use | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | B Blood and blood forming organs | 2022* | 0.68 | 958 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D01 Antifungals for dermatological use | 2022* | 2.92 | 1,249 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D01A Antifungals for topical use | 2022* | 2.87 | 1,219 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D01B Antifungals for systemic use | 2022* | 0.08 | 30 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D03 Means for wounds & ulcers treatment | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D05A Antipsoriatics for topical use | 2022* | 0.08 | 189 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D05B Antipsoriatics for systemic use | 2022* | 0.00 | 1 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D06 Antibiotics.. for dermatological use | 2022* | 7.98 | 2,313 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D06A Antibiotics for topical use | 2022* | 7.90 | 2,241 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | D06B Chemotherapeutics for topical use | 2022* | 0.10 | 73 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | G02B Contraceptives for topical use | 2022* | 0.00 | 26 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | H02 Corticosteroids for systemic use | 2022* | 0.86 | 363 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | J General antiinfectives for system.use | 2022* | 14.88 | 1,130 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | J01 Antibacterials for systemic use | 2022* | 14.69 | 1,099 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | J02 Antimycotics for systemic use | 2022* | 0.09 | 19 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | J02A Antimycotics for systemic use | 2022* | 0.09 | 19 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | J04A Drugs for treatment of tuberculosis | 2022* | 0.01 | 5 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | J04B Drugs for treatment of lepra | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | J05 Antivirals for systemic use | 2022* | 0.06 | 7 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | M05 Drugs for treatment of bone diseases | 2022* | 0.00 | 1 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | M09 Oth.drugs for musculo-skelet.disord. | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | R03 Drugs for obstruct. airway diseases | 2022* | 6.83 | 4,931 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | R03C Adrenergics for systemic use | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | R06 Antihistamines for systemic use | 2022* | 6.56 | 3,744 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | R06A Antihistamines for systemic use | 2022* | 6.56 | 3,744 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | V06A Obesity treatment diet formulations | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin: born in the Netherlands | V06C Infant formulas | 2022* | 0.00 | 0 |
Total male and female | 0 to 14 years | Origin country: The Netherlands | A02 Drugs for acid related disorders | 2022* | 0.57 | 459 |
Source: CBS. |
Table explanation
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, origin, age and sex.
Data available from 2020.
Status of the figures:
Figures for 2022 are provisional.
Changes as of December 20, 2023:
- Provisional figures for 2022 have been added, provisional figures of 2020 and 2021 have been made definite.
- Textual change: the description of drug group Y (Not filled in) has been replaced by Z (Not applicable). However, the underlying resources have remained the same. This category is assigned to products that do not have an ATC code according to the WHO ATC classification system.
When will new figures be published?
New figures will be published in the last quarter of 2024.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.
- Defined daily doses (DDD), relative
- Defined Daily Dose (DDD) is de door de WHO vastgestelde gemiddelde dagelijkse dosis van een geneesmiddel, wanneer het geneesmiddel wordt ingezet voor de hoofdindicatie, bij een onderhoudsbehandeling voor volwassenen. Deze definitie maakt het mogelijk om het gebruik van verschillende toedieningsvormen en verschillende middelen met elkaar te vergelijken.
WHO: World Health Organisation, Wereldgezondheidsorganisatie